X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes of OCV (cholera vaccines) in order to reduce the critical shortage of vaccines needed to prevent cholera globally.
Lead Product(s): Cholera Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OCV
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: International Vaccine Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 23, 2022
Details:
IVI developed the world’s first low-cost oral cholera vaccine (OCV). The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes in order to reduce the critical shortage of vaccines needed to prevent cholera globally.
Lead Product(s): Cholera Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OCV
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Wellcome
Deal Size: $6.9 million Upfront Cash: Undisclosed
Deal Type: Funding November 22, 2022
Details:
Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s Covid Vaccine, BNT162b2's global supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing facilities.
Lead Product(s): Tozinameran
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
